LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

Executive Summary

• LIR Life Sciences reported positive interim results from a comparative mouse study of a CPP‑enabled topical semaglutide formulation, showing reduced blood glucose after an oral glucose challenge versus untreated controls.
• The topical formulation achieved glucose‑lowering effects comparable to injectable semaglutide, marking a key technical milestone for the company’s transdermal delivery platform.
• Results support continued funding of ongoing comparative studies and guide next steps in formulation refinement and dose optimization.

Key Details

• Study Design: Comparative mouse model evaluating a skin‑applied CPP (cell‑penetrating peptide) formulation of semaglutide against injectable semaglutide and untreated controls.
• Interim Findings:
• Animals receiving the CPP‑formulated topical semaglutide displayed a blunted glucose spike and faster return to baseline after an oral glucose challenge, similar to the injectable group.
• Untreated control animals showed a pronounced blood‑glucose surge.
• Blood‑glucose levels in the topical group remained stable throughout the observation period.
• Technical Milestone: Demonstrates that CPP‑enabled transdermal delivery can achieve pharmacologically meaningful systemic exposure of a large peptide (semaglutide) in vivo.
• Implications: Provides preliminary in‑vivo support for LIR’s platform to deliver GLP/GIP‑based therapies needle‑free, potentially expanding treatment options for obesity and metabolic disorders.
• Next Steps:
• Refine the topical formulation and narrow dose ranges.
• Complete additional comparative studies already underway, including another GLP/GIP‑based therapy with results expected soon.
• CEO Comment: “Even at this interim stage, we are encouraged by what the study is showing… it gives us a clear basis for the next phase of work, including refining the formulation, narrowing the dose range, and completing the additional comparative studies already underway.” – Edward Mills, CEO

Notable Quotes

• Edward Mills, CEO: “Our CPP‑enabled topical formulation is producing a meaningful glucose‑lowering effect in a standard model. This is an important step because it supports the thesis of pursuing a needle‑free approach and gives us a clear basis for the next phase of work.”